Thyroid Cancer

Overview
Epidemiology
Pathophysiology
Etiology and Risk Factors
Clinical Presentation
Diagnosis
Treatment
Complications
Prognosis
Prevention
Recent Research and Advances
References & Research
Featured Videos

1. Overview

Thyroid cancer is a malignancy arising from the follicular or parafollicular (C) cells of the thyroid gland, a butterfly-shaped endocrine organ located in the anterior neck that produces thyroid hormones (T3 and T4) essential for regulating metabolism, growth, and development. Thyroid cancer is the most common endocrine malignancy and one of the most rapidly increasing cancer diagnoses worldwide, with incidence rates having tripled over the past three decades, largely attributed to increased detection of small, subclinical tumors through widespread use of diagnostic ultrasound and cross-sectional imaging.

Thyroid cancer is classified into four major histological subtypes with markedly different biological behaviors and prognoses: papillary thyroid carcinoma (PTC), the most common subtype accounting for 80-85% of cases, characterized by an excellent prognosis with >98% 10-year survival; follicular thyroid carcinoma (FTC), comprising 10-15% of cases, with a slightly more aggressive behavior and propensity for hematogenous metastasis; medullary thyroid carcinoma (MTC), arising from the parafollicular C cells that produce calcitonin, accounting for 3-5% of cases, with approximately 25% associated with inherited RET proto-oncogene mutations in the context of multiple endocrine neoplasia type 2 (MEN2); and anaplastic (undifferentiated) thyroid carcinoma (ATC), a rare but highly aggressive and nearly uniformly fatal malignancy representing 1-2% of thyroid cancers.

The molecular biology of thyroid cancer has been extensively characterized, with the BRAF V600E mutation present in approximately 45-60% of papillary thyroid carcinomas, RAS mutations in follicular variant PTC and FTC, RET/PTC rearrangements in radiation-induced PTC, and PAX8-PPARgamma fusions in FTC. These molecular markers have transformed diagnostic classification, risk stratification, and therapeutic strategies, particularly with the development of targeted therapies such as BRAF inhibitors and multi-kinase inhibitors for advanced, radioiodine-refractory disease.

2. Epidemiology

Thyroid cancer is the 12th most common cancer overall and the 5th most common cancer in women in the United States. The American Cancer Society estimated approximately 44,020 new cases in the United States in 2024 (12,300 in men and 31,720 in women), with approximately 2,170 deaths. The female-to-male ratio is approximately 3:1, one of the most pronounced sex differences of any non-reproductive malignancy. The median age at diagnosis is 51 years, younger than most solid tumors.

The global incidence of thyroid cancer has increased dramatically over the past 30 years, with age-adjusted incidence rates approximately tripling since the 1970s. This increase is overwhelmingly driven by the detection of small (<2 cm) papillary carcinomas, particularly papillary microcarcinomas (<1 cm), and is largely attributed to incidental detection through neck ultrasound, CT, MRI, and PET scans performed for unrelated indications. Autopsy studies consistently find incidental papillary microcarcinomas in 5-36% of thyroid glands examined, suggesting a vast reservoir of subclinical disease.

Despite the tripling of incidence, thyroid cancer mortality has remained relatively stable at approximately 0.5 per 100,000 population, supporting the concept that much of the increased incidence represents overdiagnosis of indolent tumors that would never have caused clinical harm. Geographic variation is notable, with the highest incidence rates reported in South Korea (where aggressive screening programs led to a 15-fold increase in diagnosis), Israel, Canada, and the United States. The overall 5-year survival rate for all thyroid cancers combined is approximately 98%, making it one of the most survivable malignancies.

3. Pathophysiology

Papillary Thyroid Carcinoma (PTC)

PTC arises from thyroid follicular epithelial cells and is characterized histologically by distinctive nuclear features: nuclear clearing ("Orphan Annie eyes"), nuclear grooves, intranuclear pseudoinclusions, and psammoma bodies (concentrically laminated calcifications). PTC is driven predominantly by mutations that activate the MAPK (mitogen-activated protein kinase) signaling pathway:

BRAF V600E mutation: The most common genetic alteration, present in 45-60% of PTC cases. This point mutation in the BRAF kinase leads to constitutive activation of the MAPK pathway, promoting cell proliferation and dedifferentiation. BRAF V600E is associated with aggressive clinicopathological features including extrathyroidal extension, lymph node metastasis, radioiodine refractoriness, and higher recurrence rates.
RET/PTC rearrangements: Found in 10-20% of sporadic PTC and up to 60-80% of radiation-induced PTC. RET/PTC1 and RET/PTC3 are the most common variants.
RAS mutations (HRAS, KRAS, NRAS): Found in 10-20% of PTC, particularly the follicular variant.
TERT promoter mutations: Present in 7-22% of PTC, associated with aggressive behavior. When coexisting with BRAF V600E, the combination identifies the highest-risk subset of PTC with significantly increased mortality.

PTC spreads primarily via lymphatic channels, with cervical lymph node metastasis present in 20-50% of cases at diagnosis (microscopic metastasis in up to 80%). Distant metastasis is uncommon (2-5%), typically to the lungs.

Follicular Thyroid Carcinoma (FTC)

FTC also arises from follicular cells but differs from PTC in its molecular profile and biological behavior. Key molecular drivers include RAS mutations (40-50%) and PAX8-PPARgamma fusion (30-40%). Unlike PTC, FTC is defined histologically by capsular and/or vascular invasion, features that cannot be assessed on fine-needle aspiration cytology (hence the need for diagnostic lobectomy for "follicular neoplasm" cytology). FTC spreads predominantly via hematogenous (blood vessel) routes to bone and lungs, rather than through lymphatics. Hurthle cell carcinoma (oncocytic variant) is considered a variant of FTC, characterized by large cells with abundant eosinophilic granular cytoplasm due to packed mitochondria. Hurthle cell carcinomas are more aggressive and less likely to take up radioactive iodine.

Medullary Thyroid Carcinoma (MTC)

MTC arises from the parafollicular C cells of the thyroid, which are derived from the neural crest and produce calcitonin. Unlike differentiated thyroid cancers, MTC does not produce thyroglobulin and does not take up radioactive iodine. Approximately 75% of MTC cases are sporadic, and 25% are hereditary, associated with germline RET proto-oncogene activating mutations in the context of multiple endocrine neoplasia type 2A (MEN2A) (MTC + pheochromocytoma + hyperparathyroidism), MEN2B (MTC + pheochromocytoma + mucosal neuromas + marfanoid habitus), or familial MTC (FMTC). Somatic RET mutations are also found in 40-60% of sporadic MTC. MTC metastasizes to cervical lymph nodes (50-70% at presentation) and can also spread to the lungs, liver, and bones.

Anaplastic Thyroid Carcinoma (ATC)

ATC is one of the most aggressive human malignancies, with a median survival of only 3-6 months. It is believed to arise through dedifferentiation of pre-existing well-differentiated thyroid carcinoma, supported by the frequent coexistence of PTC or FTC within ATC specimens. ATC has accumulated a high mutational burden including TP53 mutations (50-80%), BRAF V600E (25-45%), TERT promoter mutations (65-75%), and PI3K/AKT/mTOR pathway alterations. The tumor rapidly invades surrounding structures (trachea, esophagus, recurrent laryngeal nerve) and metastasizes widely. ATC cells lose expression of sodium-iodide symporter (NIS) and thyroglobulin, rendering the tumor refractory to radioactive iodine and thyroglobulin surveillance.

4. Etiology and Risk Factors

Radiation Exposure

Childhood radiation exposure: The most firmly established environmental risk factor. External beam radiation to the head and neck during childhood increases thyroid cancer risk in a dose-dependent linear fashion, with a latency period of 5-40 years. Risk is highest for exposure before age 5.
Nuclear accidents: The Chernobyl disaster (1986) caused a dramatic increase in childhood PTC in exposed populations, with RET/PTC rearrangements present in the majority of radiation-induced tumors.
Medical radiation: Childhood radiation therapy for conditions such as tinea capitis, enlarged tonsils/adenoids, thymus enlargement, and Hodgkin lymphoma increases risk.
Radioactive iodine (I-131) fallout exposure: Environmental exposure from nuclear testing and accidents.

Genetic Factors

RET proto-oncogene germline mutations: Causative of hereditary MTC (MEN2A, MEN2B, FMTC). Genotype-phenotype correlations guide the timing of prophylactic thyroidectomy (by age 1 for MEN2B codon M918T, by age 5 for high-risk MEN2A codons).
Family history: First-degree relatives of PTC patients have a 4-10 fold increased risk. Familial non-medullary thyroid cancer (FNMTC) accounts for 3-9% of PTC cases, defined by two or more first-degree relatives with PTC.
Hereditary syndromes: Cowden syndrome (PTEN hamartoma syndrome), familial adenomatous polyposis (FAP/Gardner syndrome), Carney complex, and Werner syndrome carry increased thyroid cancer risk.

Other Risk Factors

Female sex: 3:1 female predominance, suggesting a role for estrogen and reproductive factors.
Iodine status: Iodine deficiency is associated with increased follicular carcinoma, while iodine excess is associated with increased papillary carcinoma.
Pre-existing thyroid disease: Hashimoto's thyroiditis may be associated with slightly increased PTC risk and thyroid lymphoma.
Obesity: BMI >30 increases thyroid cancer risk by 20-30%, possibly through insulin resistance and elevated IGF-1.
Tall stature: Epidemiological association, reflecting shared growth factor pathways.

5. Clinical Presentation

Common Presentation

The most common presentation of thyroid cancer is a painless thyroid nodule discovered incidentally on physical examination or imaging performed for other indications. Thyroid nodules are extremely common, palpable in 5-7% of the adult population and detectable by ultrasound in 20-76%. However, only 5-15% of thyroid nodules are malignant. Most thyroid cancer patients are clinically euthyroid, with normal thyroid function tests, as the malignant cells typically retain insufficient functional capacity to alter systemic hormone levels.

Thyroid nodule: Firm, non-tender, may be fixed to surrounding tissues (concerning for invasion)
Cervical lymphadenopathy: Palpable, firm, non-tender lateral neck lymph nodes, particularly in PTC. May be the presenting finding in 10-15% of cases
Incidental finding on imaging: FDG-PET uptake in the thyroid (PET-positive thyroid incidentalomas have a malignancy rate of 30-35%)

Locally Advanced Disease

Hoarseness or voice change: Due to recurrent laryngeal nerve invasion, more common in advanced PTC, FTC, or ATC
Dysphagia: Difficulty swallowing from esophageal compression or invasion
Dyspnea and stridor: Airway compression or tracheal invasion, a hallmark presentation of ATC
Rapidly enlarging neck mass: Characteristic of ATC, with doubling time measured in weeks
Pain: Uncommon in differentiated thyroid cancer; persistent pain suggests aggressive histology or extrathyroidal invasion
Superior vena cava syndrome: Rare, from mediastinal extension

Subtype-Specific Features

MTC: Diarrhea (from calcitonin or prostaglandin secretion, present in 30% of cases with advanced disease), facial flushing, elevated serum calcitonin and CEA. In MEN2 context: may present with concurrent pheochromocytoma (hypertension, tachycardia, diaphoresis) or hyperparathyroidism (hypercalcemia).
ATC: Rapidly enlarging firm neck mass, compressive symptoms (dyspnea, dysphagia, hoarseness), often with fixation to surrounding structures. Median tumor size at presentation is >5 cm.

6. Diagnosis

Thyroid Ultrasound

High-resolution thyroid ultrasound is the first-line imaging modality for evaluating thyroid nodules. Sonographic features suggestive of malignancy include:

Solid hypoechoic composition
Microcalcifications (highly specific for PTC, representing psammoma bodies)
Irregular or infiltrative margins
Taller-than-wide shape on transverse view
Extrathyroidal extension
Abnormal cervical lymph nodes (round shape, loss of fatty hilum, cystic changes, microcalcifications, peripheral vascularity)

The American College of Radiology Thyroid Imaging Reporting and Data System (ACR TI-RADS) provides a standardized scoring system to stratify nodule risk and guide FNA biopsy decisions based on composition, echogenicity, shape, margins, and echogenic foci.

Fine-Needle Aspiration Biopsy (FNAB)

Ultrasound-guided FNA is the most accurate and cost-effective method for evaluating thyroid nodules. Cytological results are reported using the Bethesda System for Reporting Thyroid Cytopathology, which stratifies FNA results into six categories with associated malignancy risks:

Bethesda I: Non-diagnostic/unsatisfactory (malignancy risk 5-10%). Repeat FNA recommended.
Bethesda II: Benign (malignancy risk 0-3%). Clinical follow-up.
Bethesda III: Atypia of undetermined significance / follicular lesion of undetermined significance (AUS/FLUS) (malignancy risk 10-30%). Repeat FNA, molecular testing, or diagnostic lobectomy.
Bethesda IV: Follicular neoplasm / suspicious for follicular neoplasm (malignancy risk 25-40%). Diagnostic lobectomy recommended (FNA cannot distinguish follicular adenoma from carcinoma).
Bethesda V: Suspicious for malignancy (malignancy risk 50-75%). Lobectomy or total thyroidectomy.
Bethesda VI: Malignant (malignancy risk 97-99%). Total thyroidectomy.

Molecular Testing

Molecular testing of FNA specimens has become a valuable adjunct for indeterminate cytology (Bethesda III and IV):

ThyroSeq v3: A next-generation sequencing panel testing for mutations and fusions in 112 genes. High sensitivity (94%) and specificity (82%) for malignancy detection.
Afirma Gene Expression Classifier (GEC)/Gene Sequencing Classifier (GSC): A "rule-out" test with high negative predictive value (96%). A benign result reclassifies Bethesda III/IV nodules to observation.
BRAF V600E testing: If positive, essentially diagnostic for PTC (positive predictive value >99%).
RET mutation testing: Essential for all MTC patients to identify hereditary cases requiring screening of at-risk family members.

Staging and Risk Stratification

The AJCC 8th edition TNM staging system (2018) incorporates age at diagnosis as a key prognostic factor: patients <55 years are staged as either Stage I (no distant metastasis) or Stage II (distant metastasis present), reflecting the excellent prognosis of differentiated thyroid cancer in younger patients regardless of local extent. For patients ≥55 years, staging follows conventional T, N, and M criteria (Stages I-IVB).

The American Thyroid Association (ATA) risk stratification system classifies differentiated thyroid cancer patients into three categories for initial recurrence risk assessment:

Low risk: Intrathyroidal PTC without vascular invasion, ≤5 microscopic lymph node metastases (<0.2 cm). Recurrence risk: 1-3%.
Intermediate risk: Microscopic extrathyroidal extension, RAI-avid cervical lymph node metastasis, aggressive histology, vascular invasion, clinical N1 disease, or BRAF V600E mutation. Recurrence risk: 8-22%.
High risk: Macroscopic extrathyroidal extension, incomplete tumor resection, distant metastasis, postoperative serum thyroglobulin suggestive of distant metastasis, or pathologic N1 with any metastatic lymph node ≥3 cm. Recurrence risk: 23-46%.

7. Treatment

Surgery

Surgical resection is the primary treatment for nearly all thyroid cancers:

Total thyroidectomy: Recommended for tumors >4 cm, bilateral disease, macroscopic extrathyroidal extension, clinically apparent lymph node metastasis (cN1), or when RAI therapy is planned. Advantages include eliminating all thyroid tissue for RAI ablation and enabling thyroglobulin monitoring for recurrence.
Lobectomy (hemithyroidectomy): Acceptable for unifocal, intrathyroidal papillary carcinomas 1-4 cm without evidence of extrathyroidal extension, lymph node metastasis, or vascular invasion. Also serves as diagnostic surgery for Bethesda IV cytology. The 2015 ATA guidelines expanded the role of lobectomy as adequate treatment for low-risk differentiated thyroid cancer.
Central compartment neck dissection (level VI): Therapeutic dissection recommended for clinically involved central lymph nodes (cN1a). Prophylactic central dissection is controversial but may be considered for advanced primary tumors (T3/T4).
Lateral neck dissection (levels II-V): Performed for biopsy-proven lateral lymph node metastasis (cN1b). Typically a modified radical neck dissection preserving the sternocleidomastoid, internal jugular vein, and accessory nerve.
Prophylactic thyroidectomy for MTC: RET mutation carriers undergo prophylactic total thyroidectomy. Timing is determined by the specific RET codon mutation: within the first year of life for MEN2B (M918T), by age 5 for high-risk MEN2A codons (C634), and when calcitonin becomes elevated or by age 5-10 for moderate-risk MEN2A codons.

Radioactive Iodine (RAI) Therapy

Radioactive iodine-131 (I-131) therapy exploits the ability of differentiated thyroid cancer cells to concentrate iodine through the sodium-iodide symporter (NIS). RAI is used for:

Remnant ablation: Destruction of residual normal thyroid tissue after total thyroidectomy to facilitate thyroglobulin surveillance. Typical dose: 30-100 mCi.
Adjuvant therapy: Treatment of microscopic residual disease in intermediate- and high-risk patients. Typical dose: 100-150 mCi.
Treatment of metastatic disease: RAI-avid distant metastases (lungs, bone) may be treated with higher doses (150-200 mCi), with cumulative lifetime doses monitored to avoid bone marrow suppression.

RAI preparation requires TSH stimulation (either thyroid hormone withdrawal for 3-4 weeks or recombinant human TSH [Thyrogen] injections) and a low-iodine diet for 1-2 weeks to maximize RAI uptake. A post-therapy whole-body scan (WBS) is performed 5-7 days after RAI administration to detect previously unknown metastatic disease.

TSH Suppression Therapy

Levothyroxine (T4) therapy is prescribed after thyroidectomy at doses sufficient to suppress TSH to levels appropriate for the patient's risk category:

High-risk patients: TSH goal <0.1 mIU/L
Intermediate-risk patients: TSH goal 0.1-0.5 mIU/L
Low-risk patients (after initial treatment): TSH goal 0.5-2.0 mIU/L
Low-risk patients with excellent response: TSH can be allowed into the normal range (0.5-2.0 mIU/L)

Targeted Therapy for Advanced Disease

For patients with progressive, radioiodine-refractory differentiated thyroid cancer (RR-DTC) and advanced MTC, targeted systemic therapies have transformed management:

Sorafenib (Nexavar): Multi-kinase inhibitor approved for progressive RR-DTC. The DECISION trial demonstrated significantly improved progression-free survival (10.8 vs. 5.8 months).
Lenvatinib (Lenvima): Multi-kinase inhibitor approved for RR-DTC. The SELECT trial showed remarkable improvement in progression-free survival (18.3 vs. 3.6 months). Currently the preferred first-line agent for RR-DTC.
Dabrafenib + trametinib: BRAF + MEK inhibitor combination approved for BRAF V600E-mutant ATC. The landmark trial showed an overall response rate of 56% in this previously untreatable cancer.
Vandetanib (Caprelsa): RET and VEGFR inhibitor approved for progressive, symptomatic MTC. The ZETA trial demonstrated improved progression-free survival.
Cabozantinib (Cometriq): RET, MET, and VEGFR2 inhibitor approved for progressive MTC. The EXAM trial showed improved progression-free survival (11.2 vs. 4.0 months).
Selpercatinib (Retevmo): Highly selective RET inhibitor approved for RET-mutant MTC and RET fusion-positive thyroid cancer. The LIBRETTO-001 trial demonstrated an overall response rate of 69-73% with a favorable side-effect profile.
Pralsetinib (Gavreto): Another selective RET inhibitor approved for RET-altered thyroid cancer.

Treatment of Anaplastic Thyroid Carcinoma

ATC requires aggressive multimodal treatment:

BRAF V600E-mutant ATC: Dabrafenib 150 mg BID + trametinib 2 mg daily. This combination has dramatically improved outcomes for this previously uniformly fatal disease.
BRAF wild-type ATC: External beam radiation therapy (EBRT) combined with chemotherapy (docetaxel/doxorubicin or carboplatin/paclitaxel). Immunotherapy with checkpoint inhibitors (pembrolizumab, atezolizumab) is being actively investigated given the high tumor mutational burden and PD-L1 expression in ATC.
Surgical resection: When feasible (R0/R1 resection achievable), surgery improves outcomes in combination with adjuvant therapy.

8. Complications

Hypoparathyroidism: Inadvertent damage or removal of the parathyroid glands during thyroidectomy causes hypocalcemia. Transient hypoparathyroidism occurs in 20-30% of total thyroidectomies; permanent hypoparathyroidism in 1-4%. Requires lifelong calcium and vitamin D supplementation.
Recurrent laryngeal nerve (RLN) injury: Unilateral RLN injury causes hoarseness and voice changes, occurring in 1-2% of experienced surgeons' cases (temporary) and <1% permanently. Bilateral RLN injury is a rare but serious complication causing airway compromise requiring tracheostomy.
Hypothyroidism: Intentional after total thyroidectomy; requires lifelong levothyroxine replacement with dose titration based on TSH targets.
Radioactive iodine side effects: Sialadenitis (salivary gland inflammation and swelling), xerostomia (dry mouth), taste changes, transient nausea, and rarely bone marrow suppression with high cumulative doses. Second primary malignancies (leukemia, salivary gland tumors) are rare but documented with cumulative RAI doses exceeding 600 mCi.
Disease recurrence: Locoregional recurrence occurs in 5-20% of differentiated thyroid cancer patients, most commonly in cervical lymph nodes. Distant metastasis occurs in 5-10%, most commonly to lungs and bones.
Radioiodine-refractory disease: Approximately 5-15% of differentiated thyroid cancers lose the ability to concentrate radioactive iodine, requiring alternative treatment approaches.
Psychosocial impact: Long-term thyroid cancer surveillance, TSH suppression therapy, and the anxiety of a cancer diagnosis significantly impact quality of life despite favorable prognosis.

9. Prognosis

The prognosis of thyroid cancer varies dramatically by histological subtype. Papillary thyroid carcinoma has an overall 5-year survival rate >98% and a 10-year survival rate of 93-97%. Even patients with lymph node metastasis have excellent outcomes, with disease-specific mortality of only 1-2% for patients younger than 45. Follicular thyroid carcinoma has a slightly less favorable prognosis, with 10-year survival of 85-92%, primarily due to its propensity for hematogenous metastasis to bone and lungs.

Medullary thyroid carcinoma has an overall 10-year survival of 75-85%, with prognosis strongly dependent on stage at diagnosis. Patients with disease confined to the thyroid have a 10-year survival exceeding 95%, while those with distant metastasis have a 10-year survival of approximately 40%. Serum calcitonin doubling time is the strongest prognostic marker: calcitonin doubling time <6 months predicts aggressive disease and poor survival, while doubling time >24 months indicates indolent disease.

Anaplastic thyroid carcinoma has a dismal prognosis, with a median survival of 3-6 months and a 1-year survival rate of approximately 20%. However, the introduction of BRAF-targeted therapy (dabrafenib + trametinib) for BRAF V600E-mutant ATC has significantly improved outcomes for this molecular subset, with response rates of 56% and substantially prolonged survival compared to historical controls. The dynamic risk stratification approach, which reclassifies patients based on their response to initial therapy (excellent, indeterminate, biochemically incomplete, or structurally incomplete response), allows for individualized adjustment of surveillance intensity and TSH suppression goals over time.

10. Prevention

Minimize unnecessary radiation exposure: Limit radiation to the head and neck region in children and adolescents. Use thyroid shielding during dental and diagnostic radiography when appropriate.
Potassium iodide (KI) prophylaxis: In the event of nuclear accidents, KI administration saturates the thyroid with stable iodine, blocking uptake of radioactive I-131. Most effective when administered within 2 hours of exposure, particularly for children and young adults.
Genetic screening for RET mutations: All patients diagnosed with MTC should undergo RET oncogene testing. Identified RET mutation carriers and their at-risk family members should undergo prophylactic thyroidectomy at the age recommended for their specific mutation codon.
Avoid overdiagnosis: Current guidelines recommend against thyroid cancer screening in asymptomatic individuals and against FNA biopsy of nodules <1 cm unless highly suspicious ultrasound features are present. The US Preventive Services Task Force (USPSTF) recommends against screening for thyroid cancer in asymptomatic adults.
Adequate iodine nutrition: Maintaining adequate dietary iodine intake (150 mcg/day for adults) through iodized salt and dietary sources supports normal thyroid function. Both iodine deficiency and excess have been associated with thyroid cancer risk.
Active surveillance for low-risk papillary microcarcinoma: Growing evidence supports active surveillance (serial ultrasound monitoring without immediate surgery) as a safe alternative to surgery for papillary microcarcinomas <1 cm without concerning features. Pioneered in Japan, studies show that only 5-10% of observed microcarcinomas grow significantly over 10 years.
Maintain healthy body weight: Obesity is a modifiable risk factor associated with a 20-30% increased thyroid cancer risk.

11. Recent Research and Advances

Thyroid cancer research continues to advance across molecular diagnostics, targeted therapy, de-escalation strategies, and immunotherapy. The Thyroid Cancer Genome Atlas (TCGA) project published in 2014 provided a comprehensive molecular characterization of PTC, identifying two major molecular subtypes: BRAF-like (associated with classical PTC histology and MAPK pathway activation) and RAS-like (associated with follicular variant PTC and PI3K pathway activation). This molecular classification has refined prognostic stratification and therapeutic decision-making.

The development of highly selective RET inhibitors (selpercatinib, pralsetinib) represents a transformative advance for RET-altered thyroid cancers. Unlike earlier multi-kinase inhibitors with broad targets and significant toxicity, these selective agents specifically target RET with markedly improved efficacy and tolerability. Ongoing trials are evaluating these agents in earlier disease settings and in combination with other therapies. For anaplastic thyroid carcinoma, the combination of dabrafenib and trametinib for BRAF V600E-mutant tumors has been practice-changing, and neoadjuvant use of these agents to render previously unresectable tumors surgically amenable is an active area of investigation.

The concept of active surveillance for papillary microcarcinoma has gained substantial momentum, with prospective observational studies from Japan (Kuma Hospital and Cancer Institute Hospital) demonstrating that observation without immediate surgery is safe for appropriately selected low-risk microcarcinomas, with tumor growth beyond 3 mm observed in only 5-12% of patients over 10 years and no disease-specific mortality. Active surveillance trials are now underway in the United States and Europe. Redifferentiation therapy using MAPK pathway inhibitors (dabrafenib, trametinib, selumetinib) to restore radioiodine avidity in previously RAI-refractory tumors is showing promise in clinical trials, with selumetinib demonstrating restored RAI uptake in 60-70% of treated patients. Immunotherapy with checkpoint inhibitors (pembrolizumab, nivolumab, atezolizumab) is being evaluated in advanced thyroid cancers, particularly ATC which exhibits high PD-L1 expression and tumor mutational burden.

12. References & Research

Historical Background

The thyroid gland was first described by Andreas Vesalius in 1543, though its function remained unknown for centuries. Theodor Billroth and Theodor Kocher pioneered thyroid surgery in the late 19th century, with Kocher receiving the Nobel Prize in Physiology or Medicine in 1909 for his work on the physiology, pathology, and surgery of the thyroid gland. Radioactive iodine therapy for thyroid cancer was first used by Saul Hertz and Arthur Roberts at Massachusetts General Hospital in 1941, establishing the paradigm of targeted radionuclide therapy. The fine-needle aspiration biopsy technique for thyroid nodule evaluation was developed in the 1950s and standardized with the Bethesda System for Reporting Thyroid Cytopathology in 2007. The discovery of RET proto-oncogene mutations in hereditary MTC by Mulligan et al. in 1993 and the BRAF V600E mutation in PTC by Kimura et al. in 2003 ushered in the molecular era of thyroid cancer classification and targeted therapy.